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Abstract
Background: The antimicrobial resistance is a global problem, probably due to the indiscriminate and irrational
use of antibiotics, prescriptions for incorrect medicines or incorrect determinations of dose, route and/or duration.
Another consideration is the uncertainty of patients receiving antibiotics about whether the quality of a generic
medicine is equal to, greater than or less than its equivalent brand-name drug. The antibiotics behaviors must be
evaluated in vitro and in vivo in order to confirm their suitability for therapeutic use.
Methods: The antimicrobial activities of Meropenem and Piperacillin/Tazobactam were studied by microbiological
assays to determine their potencies (content), minimal inhibitory concentrations (MICs), critical concentrations and
capacity to produce spontaneous drug-resistant mutants.
Results: With respect to potency (content) all the products fulfill USP requirements, so they should all be
considered pharmaceutical equivalents. The MIC values of the samples evaluated (trade marks and generics) were
the same for each strain tested, indicating that all products behaved similarly. The critical concentration values
were very similar for all samples, and the ratios between the critical concentration of the standard and those of
each sample were similar to the ratios of their specific antibiotic contents. Overall, therefore, the results showed no
significant differences among samples. Finally, the production of spontaneous mutants did not differ significantly
among the samples evaluated.
Conclusions: All the samples are pharmaceutical equivalents and the products can be used in antimicrobial
therapy.
Background
In the past few decades, antimicrobial resistance has
been seen globally in several pathogenic microorgan-
isms, including some that were antibiotic-sensitive until
recently. This is probably due to the indiscriminate and
irrational use of these medicines [1,2]. According to the
World Health Organization [1], the increase in antimi-
crobial resistance stems from a number of factors,
including lack of knowledge about it among prescribing
doctors, which leads to unnecessary prescriptions.
Inadequate diagnosis or lack of diagnosis also leads to
the use of antimicrobials against a “possible infection”.
Also, prescriptions for incorrect medicines or incorrect
determinations of dose, route and/or duration of treat-
ment often occur in response to pressure from compa-
nies or patients and the desire for profit. It has been
recognized that medical visitors or commercially
oriented publications are the main sources of informa-
tion about medicines.
Another important consideration is the uncertainty of
patients receiving antibiotics about whether the quality
of a generic medicine is equal to, greater than or less
than its equivalent brand-name drug. The belief that
“the more expensive the product, the more effective” is
shared by some doctors and pharmacists. This miscon-
ception leads to unnecessary use of the newest antibio-
tics simply because they are more expensive and broad-
spectrum, and this in turn promotes the selection of
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without real benefit [1]. Within this myth of “the more
expensive, the more effective” we can include innovative
products and generic ones because the public tends to
believe that the generic product, because of its low
price, is of bad quality, and therefore ineffective. For all
medicines (generic or brand-name), especially antibio-
tics, effectiveness and safety are vital qualities; without
them, the health of the patient is at risk. To remove any
doubts about antibiotics, we must evaluate their beha-
viors in vitro and in vivo in order to confirm their suit-
ability for therapeutic use.
In order to dispel doubts about the efficacy of generic
antibiotics, arising from complaints from the medical
community and reported in the literature and at inter-
national meetings [3-5], our group decided to conduct a
broad-based study focusing on the quality and effective-
ness of commercial antibiotics in our country (Colom-
bia). We have already studied the effectiveness of some
compounds using biological assays with microorganisms:
Ceftriaxone, Cefotaxime, Ceftazidime, Ampicillin/Sul-
bactam and Imipenem/Cilastatin. The results have
shown that experimental, brand-name and generic pro-
ducts are pharmaceutical equivalents; they all fulfill the
requirements of the U. S. Pharmacopoeia (XXVIII) in
relation to their activities [6].
In this paper, we present a comparative study of Mer-
openem and Piperacillin/Tazobactam using commercial
products (experimental, brand-name and generic). We
evaluated their antimicrobial activities by determining
their potencies, critical concentrations, minimal inhibi-
tory concentrations and minimal lethal concentrations.
In respect of these parameters, all the products meet the
proper standards of quality for pharmaceutical products,
so we conclude that they all exhibit the same level of
antimicrobial activity.
Methods
Microorganisms
To validate the microbiological assay for evaluating the
potencies of Meropenem and Piperacillin, we used
Bacillus subtilis ATCC 6633, Staphylococcus aureus
ATCC 29737 and ATCC 6538p, Pseudomonas aerugi-
nosa ATCC 25619 and ATCC 9027, Micrococcus luteus
ATCC 9341, Escherichia coli ATCC 10536, Klebsiella
pneumoniae ATCC 10031 and Streptococcus faecalis.
For MIC and MLC studies we used Acinetobacter bau-
manii strains 59, 139, 147 and 173, vancomycin-resis-
tant Enterococcus gallinarum, Streptococcus faecalis
ATCC 29212, a nosocomial strain 319623 and a vanco-
mycin-sensitive strain, Escherichia coli strains 39, 50 and
69, Klebsiella pneumoniae strains 1, 43, 63, 65 and 207,
Pseudomonas aeruginosa strains 42, 74, 151 and 157,
and Staphylococcus aureus strains 287, 291 and ATCC
25923. All microorganisms were grown in Mueller Hin-
ton (MH) broth (incubated at 35°C for 24 h). Each
s t r a i nw a st h e np l a t e do nM Ha g a rt oo b t a i ni s o l a t e d
colonies, which were then used to make larger cultures
in MH medium. The cultures were harvested with cryo-
preservation broth. A portion of each was kept in a
cryovial at -70°C, while the other portion was used to
prepare a suspension with 25% transmittance at 600 nm
(25%T) to develop in vitro assays. These suspensions
were kept in cryovials at -70°C.
Analytical Bioassay
This was established and validated for Meropenem and
Piperacillin/Tazobactam. First, the most appropriate
microorganisms were selected, the proper concentration
range was determined, and the linearity, precision, speci-
ficity and stability of the compound in question were
assessed [6]. All samples were then evaluated with the
analytical bioassay under the chosen conditions.
Minimal Inhibitory Concentration (MIC) and Minimal
Lethal Concentration (MLC)
Assays to assess these parameters were developed in two
parts. (1) Preparation of inocula: the number of colony
forming units (CFU) was determined for each suspen-
sion at 25%T in order to prepare inocula of 1-5 × 10
6
CFU/ml. (2) MIC and MLC determination by micro-
dilution: samples were diluted to 2 mg/ml for evalua-
tion. Using a multichannel pipette, 100 μl of antibiotic
sample was placed in each well of a 96-well ELISA
plate, with 200 μl in column 12. Next, 100 μlo ft h e
antibiotic solution (2 mg/ml) was placed in the first col-
umn and thoroughly mixed by pipetting. From these
wells, 100 μl was added to the second column and
mixed, and this procedure was repeated up to column
10, after which the 100-μl portion was discarded. Col-
umns 11 and 12 were positive and negative controls,
respectively. Each row (A to H) represented a different
sample to be analyzed. Each inoculum (100 μl) was then
pipetted into each microplate, which was incubated at
37°C for 24 h. Growth in the wells was assessed. The
lowest dilution showing no growth, the first dilution
with growth, and the two controls were plated on to
MH agar. The MIC was defined as the lowest dilution
that showed no growth on the ELISA plate but showed
growth on MH agar; the MLC was defined as the lowest
dilution that did not show growth on either the ELISA
plate or MH agar [7].
Critical Concentration (CC)
The CC was determined similarly to the analytical
bioassay. The inocula for MIC and MLC determination
and serial two-fold dilutions of each sample from 500 to
0.244 μg/ml were used. The halo of inhibition was mea-
sured, and the crown length X was calculated (inhibition
halo diameter minus reservoir diameter divided by 2).
Log concentration vs. X
2 was plotted, and linear
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is equivalent to the log of the CC [7].
Spontaneous mutants
Spontaneous mutation was analyzed similarly to the
analytical bioassay. Again, the inocula for MIC and
MLC determination were applied. Specific microorgan-
isms and dilutions were selected after determination of
critical concentrations. On each plate, a dilution of the
USP standard and samples of the same concentration
were used.
Samples
Commercial products purchased from the pharmacies of
different hospitals in Bogotá, D. C. Colombia, were ana-
lyzed. They included innovator (MERONEM®, TAZO-
CIN®), trademark products and generic products of
Meropenem and Piperacillin/Tazobactam. All the sam-
ples declared the contents were 1 g. They were all
diluted in sterile water in 100 ml volumetric flasks. The
solutions were divided into 5 ml fractions for storage at
-70°C; they were diluted to 1 mg/ml to develop the ana-
lytical bioassays and to 2 mg/ml for MIC and MLC
assays.
Results
Analytical Bioassay
Microorganism Selection
The selection criteria were well-defined edges on inhibi-
tion haloes, halo diameters no greater than 30 to 35
mm, and no generation of spontaneous mutants under
antibiotic treatment [8,9]. Figures 1 and 2 show the
responses of various microorganisms to Meropenem
and Piperacillin/Tazobactam, respectively. On the basis
of these results, B. subtilis ATCC 6633 was selected for
further experiments because it fulfilled all the criteria
when treated with Meropenem and Piperacillin/
Tazobactam.
Determination of culture medium pH, incubation time and
concentration range
The results for Meropenem showed that pH 8 is optimal
because the inhibition haloes were well defined at that
pH. In the case of Piperacillin/Tazobactam, the opti-
mum pH was between 6.0 and 6.5. Therefore, the assay
for Meropenem is best carried out in antibiotic medium
number 11 and the assay for Piperacillin/Tazobactam in
antibiotic medium number 1.
The assays for both antibiotics require between 8 and
10 h incubation. This is less than many common assays,
which require between 18 and 24 h.
Ten concentrations were used (two-fold dilutions from
250 to 0.488 μg/ml for Meropenem and from 1000 to
1.9531 μg/ml for Piperacillin/Tazobactam). Table 1
shows that linearity was best in the range between C5
and C9 (15.62 to 0.9976 μg/ml) (R
2 = 0.9996). For prac-
tical reasons, however, the range was adjusted to 25 μg/
ml to 1.5625 μg/ml, which also showed good linearity
(R
2 = 0.9996, Figure 3).
With Piperacillin/Tazobactam, our analysis demon-
strated that the concentrations between C5 and C10
generated inhibition haloes of the appropriate diameter,
so this range was evaluated (Figure 4). For concentra-
tions between C1 and C4, the inhibition zones had dia-
meters greater than 30 mm. Table 2 shows the range
between C5 to C9 to be the most linear (R
2 = 0.9989).
Figure 1 Bioassay of Meropenem (USP standard) against (A) Bacillus subtilis ATCC 6633, (B) Escherichia coli ATCC 10536, (C) Klebsiella
pneumoniae ATCC 10031, (D) Micrococcus luteus ATCC 9341, (E) Pseudomonas aeruginosa ATCC 25619 and (F) Staphylococcus aureus
ATCC 29737.
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In Tables 3 and 4, antibiotic concentration correlates
well with the diameter of the zone of inhibition.
From this point on, the selected concentrations will be
designated C1 to C5 for clarity.
Precision
The reproducibility and between-days precision of our
assays were evaluated in several ways. Reproducibility
was studied by determining the coefficient of variation.
This was less than 1%, which is acceptable for analytical
assays in the pharmaceutical industry. The Cochran test
was also applied, and the results showed that the var-
iances at each concentration were equivalent. Finally,
ANOVA for each concentration demonstrated no signif-
icant differences between two samples run on the same
day (Table 5).
The between-days precision was also analyzed.
ANOVA showed that for the antibiotics evaluated, the
results of assays performed on different days did not dif-
fer significantly (Table 6).
Stability
The stability of each compound during the experimental
period was verified. Solutions of Meropenem and Piper-
acillin/Tazobactam (1 mg/ml; USP Standard) were incu-
bated at 37°C, and samples were taken after 0, 6, 12, 24,
and 48 h and six days of incubation. The corresponding
dilutions were then evaluated, and the results were
plotted and compared to reveal any reduction in anti-
biotic activity (i.e., a decrease in the diameter of the
zone of inhibition).
From the equation y=m x+b , where y represents the
inhibition zone diameter and x represents the log of the
concentration, changes in the b v a l u ei n d i c a t ec h a n g e s
in activity. If there is no change in the intercept, the
antibiotic is stable. If the b value decreases, this indi-
cates instability or a loss of activity.
In the case of Meropenem, the solution showed a
slight decrease in the intercept value after 24 h incuba-
tion (Table 7). From this result, it appears that the
molecule remained stable during our assays.
Piperacillin/Tazobactam showed more interesting
results. After 6 and 12 h the solution was more active,
indicated by an increase in the intercept value (Table 7).
In other assays under different conditions (incubation at
4°C or 25°C), the solutions showed the same trend
Figure 2 Bioassay of Piperacillin (USP standard)/Tazobactam against (A) Bacillus subtilis ATCC 6633, (B) Klebsiella pneumoniae ATCC
10031, (C) Micrococcus luteus ATCC 9341, (D) Pseudomonas aeruginosa ATCC 25619, (E) Staphylococcus aureus ATCC 29737 and (F)
Streptococcus faecalis. Cited on page 6.
Table 1 Evaluation of the range of concentrations for
Meropenem (USP standard)
Concentration Range Equation
From To Slope Intercept R
2
C1 C9 3.8469 15.355 0.995
C1 C5 4.288 13.36 0.9861
C2 C6 3.4631 16.437 0.9911
C3 C7 3.5659 15.967 0.9881
C4 C8 3.6377 15.735 0.9878
C5 C9 3.8575 15.374 0.9976
C6 C10 3.9901 15.42 0.9945
Table 2 Evaluation of the range of concentrations of
Piperacillin (USP standard)/Tazobactam
Concentration Range Equation
From To Slope Intercept R
2
C5 C9 2.5554 9.8253 0.9989
C6 C10 2.7968 9.1638 0.992
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(HPLC) or mass spectrometry would be necessary to
identify any structural or conformational change in the
compound that could explain this activity increase.
Most intriguingly, the activity returned to its initial
levels after 24 h.
Specificity
Solutions of the antibiotics were incubated at 50°C. The
Meropenem solution lost its activity after 22 days,
meaning that it was the only molecule in solution
responsible for the antimicrobial activity. The activity of
Piperacillin/Tazobactam was lost after six days.
Sample analysis
The samples were analyzed in two groups. The first was
used when the assay was being validated, and the second
to evaluate antimicrobial activity by determining the
MIC, MLC and CC values for each antibiotic. The
results were quantified using the statistical method
described by Hewitt (1977). Table 9 shows the content
of each antibiotic in the samples purchased, and in each
Figure 3 Calibration curve of ten concentrations of Meropenem to determine the optimal test range.
Figure 4 Calibration curve with 10 concentration levels of Piperacillin/Tazobactam to determine the optimal test range.
Silva et al. BMC Clinical Pharmacology 2010, 10:3
http://www.biomedcentral.com/1472-6904/10/3
Page 5 of 13case the values fulfill the criteria laid out by USP 29 NF
24 for intravenous Piperacillin and Meropenem: “...Con-
tents no less than 90% and no more than 120% of
Piperacillin, calculated on anhydrous base of the
quantity registered of Piperacillin” and “...Contents
no less than 90% and no more than 120% of Merope-
nem, calculated on anhydrous base of the quantity
registered of Meropenem.”
Minimal inhibitory and lethal concentrations
Using previously described methods, the samples were
analyzed in groups of seven per plate, each plate being
inoculated with a single microorganism. The first row of
the plate corresponded to the USP standard; the other
seven rows contained the samples. Figure 5 shows the
results for Piperacillin/Tazobactam. The plate shows the
same performance for the standard as for the samples.
That is, growth was inhibited at the same concentra-
tion of each sample. After replication on to MH agar,
there was no growth in concentrations C1 to C5 or
C12, but there was growth in C6 to C11. This means
that the antibiotic has an MLC but no MIC. The MLC
is C5 for the USP standard and for all the samples. For
all samples, using all microorganisms evaluated, the
results showed the same performances for both mole-
cules (Tables 10 and 11 include results for only some
samples, as illustration).
Critical concentration (CC)
The CC is the minimal concentration that inhibits
microorganism growth. It is reached at the limit of the
inhibition halo. It is a measure of the microorganism’s
sensitivity and can be two to four times greater than the
MIC, which is determined under different conditions.
The CC can be defined mathematically as Ln(CC) = Ln
(CO)-X
2/DTO, where CC is the critical concentration,
CO is the antibiotic concentration in the reservoir, X is
the length of the crown (see above), D is the diffusion
coefficient, and TO is the critical time. The intercept of
a plot of Ln (CO) vs. X
2 is the Ln of CC [7].
Figure 6 shows the different behaviors of the microor-
ganisms tested with Meropenem and Piperacillin/Tazo-
bactam standards. In Figures 6A and 6B, the inhibition
haloes are very diffuse, whereas Figures 6C and 6D cor-
respond to microorganisms with well-defined haloes.
Some microorganisms exhibited growth of spontaneous
mutants (e.g., Figure 6D), allowing a new means of com-
paring the performances of the products tested to be
developed. A well-defined inhibition halo was the selec-
tion criterion for evaluating CC. For the Meropenem
assay, P. aeruginosa 151 and 157 and A. baumanii 148
and K. pneumoniae were selected, and for Piperacillin/
Tazobactam, the selected microorganisms were E. faeca-
lis, E. faecalis ATCC 29212, P. aeruginosa 42, 74 and
151 and S. aureus 287. Figure 7 shows the correlation of
X
2 with the log of antibiotic concentration. The equa-
tion is y = 0.0203x + 1.4183, and b is therefore 1.4183.
The CC is equivalent to antilog (1.4183), i.e., 26.2 μg/ml.
T h eC Cv a l u e sf o rt h ed i f f e r e n tM e r o p e n e ma n d
Piperacillin/Tazobactam samples showed no significant
differences, meaning that the products behaved in simi-
lar ways against the different microorganisms tested
(Tables 12 and 13). On this basis, the generic products
manufactured to meet all the quality standards applied
to pharmaceutical products perform as well as the new-
est versions of those products.
Table 3 Evaluation of linearity for Meropenem and Piperacillin/Tazobactam
Experimental t Theoretical t Decision
Test HYPOTHESIS Meropenem Piperacillin
Slope H0: m = 0 2.684 2.16 Reject H0
H1:m≠ 0 7.677
Intercept H0: b = 0 18.025 Reject H0
H1:b≠ 0 47.901 2.16
Correlation H0: R = 0 58.41 23.381 2.16 Reject H0
H1:R≠ 0
Table 4 Regression analysis by analysis of variance (ANOVA).
Experimental t
Test HYPOTHESIS Meropenem Piperacillin Theoretical t Decision
H0: There is no regression 3494.54 324.89 3.67 Reject H0
Regression H1: There is regression
H0: There is no deviation
Linearity from linearity
Deviation H1: There is a deviation 0.3513 3.71 3.71 Accept H0
from linearity
Silva et al. BMC Clinical Pharmacology 2010, 10:3
http://www.biomedcentral.com/1472-6904/10/3
Page 6 of 13In addition, the ratio between sample CC and stan-
dard CC is similar to the ratio of antibiotic contents. In
others words, all samples perform the same with regard
to their antimicrobial activities in vitro (Tables 14 and
15).
Spontaneous mutants
It was noted in the previous assays that some strains
produced spontaneous mutants (Figure 6), indicated by
the appearance of colonies within the inhibition halo.
Therefore, an assay to assess spontaneous mutation was
developed with appropriate concentrations of antibiotics.
Each experimental set-up included an agar plate inocu-
lated with the test strain. Of the six reservoirs, two con-
tained standard solutions and the other four contained
sample solutions, as shown in Figure 8. The numbers of
mutants produced by the standard and sample solutions
were counted after incubation.
For Meropenem, the strains selected were A. bauma-
nii 147 as a control strain (showing no production of
spontaneous mutants), A. baumanii 189, E. coli 39 and
69, and K. pneumoniae 43 and 63. For Piperacillin/Tazo-
bactam, the strains selected were P. aeruginosa 151 as a
control strain (showing no production of spontaneous
mutants), P. aeruginosa 74 and A. baumanii 189. After
Table 5 ANOVA of the reproducibility of assays using
Meropenem and Piperacillin/Tazobactam
Concentration Experimental F Theoretical
F
Decision
Meropenem Piperacillin
C1 2.9136 2.684 5.99 Accept
H0
C2 3.9852 3.025 5.99 Accept
H0
C3 1.1247 1.009 5.99 Accept
H0
C4 0.4746 0.395 5.99 Accept
H0
C5 0.4938 0.412 5.99 Accept
H0
Table 6 ANOVA of the between-days precision of assays
using Meropenem and Piperacillin/Tazobactam
Concentration Experimental F Theoretical
F
Decision
Meropenem Piperacillin
C1 0.2747 0.6425 5.99 Accept
H0
C2 0.0169 0.2342 5.99 Accept
H0
C3 0.6447 0.4756 5.99 Accept
H0
C4 0.8572 0.9325 5.99 Accept
H0
C5 0.0712 0.123 5.99 Accept
H0
Table 7 Stability of Meropenem and Piperacillin/
Tazobactam in water for injection at 37°C
Time Meropenem Piperacillin/Tazobactam
Slope Intercept R
2 Slope Intercept R
2
0 hours 4.1977 16.556 0.9922 2.7549 9.2827 0.9969
6 hours ND ND ND 2.717 14.247 0.9946
12 hours ND ND ND 2.7162 16.39 0.9986
24 hours 4.4628 15.921 0.9976 2.6777 9.4456 0.9896
48 hours 4.1291 13.257 0.9847 3.2429 7.1086 0.9806
6 days 4.1659 5.671 0.9998 2.5459 7.0209 0.9603
ND: Not determined
Table 8 Stability of Piperacillin/Tazobactam in water for
injection at 4°C and 25°C
Time 4°C 25°C
Slope Intercept R
2 Slope Intercept R
2
0 hours 2.8549 9.2827 0.9969 2.7549 9.2827 0.9969
6 hours 2.8705 10.204 0.9949 2.7902 10.32 0.9892
12 hours 2.8234 13.45 0.9895 2.7247 13.355 0.9838
24 hours 2.8507 10.185 0.99 2.7927 9.4542 0.9908
48 hours 2.8802 8.9856 0.9955 2.8346 9.4962 0.9929
6 days 2.8158 9.4177 0.9987 2.8067 7.2892 0.9995
Table 9 Contents of the commercial samples
Samples Piperacillin/Tazobactam Meropenem
Group 1 Group 2 Group 1 Group 2
1 103.9 103.6 100.85 107.5
2 99.0 115.8 94.9 109.5
3 116.0 109.7 93.52 105.3
4 110.8 109.4 94.30 116.9
5 119.2 108.7 91.92 104.5
6 1156 105.3 97.75 105.9
7 110.6 110.5 94.02 107.2
8 113.9 111.3 94.64 115.7
9 114.7 104.2 90.76 107.2
10 116.2 107.9 92.89 103.3
11 111.2 116.8 93.32 105.7
12 112.4 117.6 95.28 107.1
13 114.6 114.3 95.29 102.5
14 116.2 108.9 92.86 103.4
15 108.2 110.1 93.43 106.2
16 114.1 108.5 93.84 104.5
17 117.9 112.6 94.22 105.1
18 110.3 104.9 97.32 106.7
19 114.8 105.8
20 111.9 107.1
21 109.9
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no significant differences in the production of sponta-
neous mutants for any of the strains tested.
Discussion
The activity of an antibiotic can be assessed under con-
trolled conditions by comparing the inhibition of growth
of sensitive microorganisms by known concentrations of
that antibiotic with a reference standard, producing
meaningful results by well characterized methods [9-11].
The experiment to evaluate assay performance showed
that it fulfilled the requirements (linearity, repeatability,
precision). In the case of Meropenem, the best linearity
was shown over the range 25 μg/ml to 1.5625 μg/ml,
where the correlation was highest (R
2 = 0.9996). For
Piperacillin/Tazobactam, the range from 62.5 μg/ml to
Table 10 Determination of MIC and MLC for Meropenem
Strain MIC (μg/ml) MLC (μg/ml)
Std M1 M2 Std M1 M2
Ps. aeruginosa 151 3.9 3.9 3.9 7.8 7.8 7.8
Ps. aeruginosa 157 15.6 15.6 15.6 31.3 31.3 31.3
Ps. aeruginosa ATCC
25619
31.3 31.3 31.3 62.5 62.5 62.5
Ps. aeruginosa 74 31.3 31.3 31.3 62.5 62.5 62.5
Ps. aeruginosa 142 15.6 15.6 15.6 31.3 31.3 31.3
A. baumanii 59 62.5 62.5 62.5 125 125 125
A. baumanii 147 15.6 15.6 15.6 31.3 31.3 31.3
A. baumanii 173 0.98 0.98 0.98 1.95 1.95 1.95
A. baumanii 189 15.6 15.6 15.6 31.3 31.3 31.3
E. coli 39 3.91 3.91 3.91 7.8 7.8 7.8
E. coli 50 62.5 62.5 62.5 125 125 125
E. coli 69 31.3 31.3 31.3 125 125 125
E. coli ATCC 13706 ≥ 500 ≥ 500 ≥ 500 ≥ 500 ≥ 500 ≥ 500
S. faecalis ≥ 500 ≥ 500 ≥ 500 ≥ 500 ≥ 500 ≥ 500
S. faecalis ATCC 29212 31.3 31.3 31.3 62.5 62.5 62.5
S. faecalis ATCC 319623 31.3 31.3 31.3 62.5 62.5 62.5
E. gallinarum 15.6 15.6 15.6 31.3 31.3 31.3
K. pneumoniae 1 62.5 62.5 62.5 125 125 125
K. pneumoniae 43 250 250 250 ≥ 500 ≥ 500 ≥ 500
K. pneumoniae 63 31.3 31.3 31.3 125 125 125
K. pneumoniae 65 15.6 15.6 15.6 31.3 31.3 31.3
K. pneumoniae 207 3.9 3.9 3.9 7.8 7.8 7.8
K. pneumoniae
ATCC10031
125 125 125 250 250 250
Figure 5 MIC and MLC assay for Piperacillin/Tazobactam.
Table 11 Determination of MIC and MLC for Piperacillin/
Tazobactam
Strain MIC (μg/ml) MLC (μg/ml)
Std M1 M2 Std M1 M2
A. baumanii (A. b.) 59 500 500 500 1000 1000 1000
A. baumanii 139 500 500 500 1000 1000 1000
A. baumanii 147 500 500 500 1000 1000 1000
A. baumanii 173 Nd Nd Nd 125 125 125
S. faecalis (S. f.) Nd Nd Nd 31.25 31.25 31.25
S. faecalis ATCC 29212 Nd Nd Nd 250 250 250
S. faecalis ATCC
319623
1000 1000 1000 >1000 >1000 >1000
E. gallinarum (E. g.) 3.95 3.95 3.95 7.81 7.81 7.81
E. coli (E. c.) 39 Nd Nd Nd 7.81 7.81 7.81
E. coli 50 1000 1000 1000
E. coli 69 62.25 62.25 62.25 250 250 250
K. pneumoniae (K. p.)
1
Nd Nd Nd 62.51 62.51 62.51
K. pneumoniae 43 R R R R R R
K. pneumoniae 63 Nd Nd Nd 1000 1000 1000
K. pneumoniae 65 Nd Nd Nd 500 500 500
K. pneumoniae 207 R R R R R R
Ps. aeruginosa (P. a.)
42
Nd Nd Nd 7.81 7.81 7.81
Ps. aeruginosa 74 125 125 125 250 250 250
Ps. aeruginosa 151 31.25 31.25 31.25 62.51 62.51 62.51
Ps. aeruginosa 157 62.51 62.51 62.51 125 125 125
St. aureus (S. a.) 287 Nd Nd Nd 7.81 7.81 7.81
St. aureus 291 31.25 31.25 31.25 62.51 62.51 62.51
St. aureus 25923 Nd Nd Nd 31.25 31.25 31.25
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Page 8 of 133.906 μg/ml was the most linear, with an R
2 value of
0.9989. The reproducibility and between-days precision
of both assays had coefficients of variation less than 1%,
and ANOVA showed no significant differences at any
concentration. Antibiotic activity remained stable over
the course of the assay at the selected temperature.
Finally, the inhibition assay results were due only to the
molecules evaluated. In conclusion, the assay was exact
and accurate, with reproducible results.
Our results with Meropenem were generally similar to
those of Mendez et al. (2005), but with some differences.
Our work used B. subtilis ATCC 6633 as a test strain,
w h i l et h e ys e l e c t e dM. luteus ATCC 9341. We used ten
concentrations to ensure better statistical analysis; the
other study only used three. However, Mendez et al.
confirmed their results using HPLC. Similar results were
reported by Zuluaga et al. (2009), who evaluated other
antibiotics (Amikacin, Gentamicin and Vancomicyn).
We conclude that antibiotics can be evaluated by estab-
lished bioassays using an appropriate test microorganism
and conditions, even though some evidence indicates
high variability in bioassays.
Analysis of commercial versions of the antibiotics
tested (innovator, trade mark and generic products)
indicated that all the samples can be considered phar-
maceutical equivalents because they fulfill the stan-
dards of the USP Pharmacopoeia (Table 9). Zuluaga et
al. (2009) proposed a comparison of performances of
all samples by linear correlation against the perfor-
mances of an innovator to determine pharmaceutical
equivalence. First, the content is determined in a com-
parison against USP standard (the so-called gold
Figure 6 Zones of growth inhibition produced by
Meropenem against (A) K. pneumoniae ATCC 10031, (B) K.
pneumoniae 65, (C) P. aeruginosa 151, and (D) A. baumanii
147.
Table 12 Critical concentrations for different samples of
Meropenem against different microorganisms.
Sample Critical Concentration (μg/ml)
P. a. 151 P. a. 157 E. c.6 9 E. c.5 0 A. b.
147
K. b.6 3
Standard 3.253 0.437 0.512 0.439 1.533 0.107
M1 3.474 0.467 0.547 0.469 1.637 0.114
M2 3.461 0.465 0.545 0.467 1.631 0.114
M3 3.490 0.469 0.549 0.471 1.645 0.115
M4 3.660 0.492 0.576 0.494 1.725 0.120
M5 3.377 0.454 0.531 0.456 1.591 0.111
M6 3.403 0.457 0.536 0.459 1.604 0.112
M7 3.461 0.465 0.545 0.467 1.631 0.114
M8 3.692 0.496 0.581 0.498 1.740 0.121
M9 3.445 0.463 0.542 0.465 1.623 0.113
M10 3.390 0.455 0.534 0.457 1.597 0.111
M11 3.409 0.458 0.537 0.460 1.607 0.112
M12 3.445 0.463 0.542 0.465 1.623 0.113
M13 3.377 0.454 0.531 0.456 1.591 0.111
M14 3.338 0.448 0.525 0.450 1.573 0.110
M15 3.425 0.460 0.539 0.462 1.614 0.113
M16 3.373 0.453 0.531 0.455 1.590 0.111
M17 3.380 0.454 0.532 0.456 1.593 0.111
M18 3.419 0.459 0.538 0.461 1.611 0.112
M19 3.455 0.464 0.544 0.466 1.628 0.114
M20 3.435 0.461 0.541 0.464 1.619 0.113
Table 13 Critical concentrations of different samples of
Piperacillin/Tazobactam against various microorganisms.
Sample Critical Concentration (μg/ml)
S. f. S. f.
29212
E. g. P. a
42
P. a
74
P. a.
151
S. a.
287
Standard 16.069 29.648 26.182 23.714 24.210 17.458 35.400
M1 16.696 30.775 27.386 24.662 25.348 18.296 36.887
M2 18.399 33.918 29.847 27.200 27.745 19.955 40.604
M3 17.500 32.198 28.303 25.611 26.268 18.977 38.586
M4 17.451 32.228 28.512 25.658 26.244 18.977 38.444
M5 17.403 32.020 28.355 25.706 26.147 18.907 38.374
M6 16.809 31.042 27.439 24.876 25.324 18.296 37.170
M7 17.516 32.554 28.695 26.061 26.583 19.117 38.869
M8 18.014 33.325 29.559 26.749 27.261 19.588 39.648
M9 16.905 31.160 27.465 25.018 25.614 18.401 37.099
M10 17.098 31.694 27.936 25.255 25.760 18.663 37.949
M11 18.576 34.214 30.319 27.318 28.036 20.252 41.029
M12 19.107 35.311 31.340 28.290 28.810 20.793 42.197
M13 18.174 33.503 29.769 26.820 27.358 19.867 40.214
M14 17.500 32.376 28.721 25.777 26.244 19.047 38.728
M15 17.757 32.880 28.983 26.275 26.752 19.344 39.082
M16 17.355 31.991 28.303 25.540 26.026 18.855 38.232
M17 17.982 32.939 29.245 26.512 26.922 19.501 39.613
M18 16.937 31.427 27.727 24.947 25.639 18.418 37.276
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Page 9 of 13standard). In that study, the performance of all samples
was similar to the standard, and the results were accu-
rate and reproducible. Therefore, it is redundant to
compare the behaviors of novel drugs against other
samples. It is sufficient to determine whether they ful-
fill the standards of the appropriate regulatory agency
because this can be shown using exact, accurate and
reproducible methods.
It has been proposed that generic antibiotics behave
differently from the innovator product against patho-
genic microorganisms [4-6]. This is possible if the gen-
eric antibiotic does not fulfill quality standards for that
pharmaceutical product (purity, content, etc.). For
instance, contaminants in generic drugs may interfere
with their antibiotic activities.
The MIC and MLC results obtained with different
pathogenic strains showed no differences among sam-
ples (Tables 10 and 11). This is probably because the
samples were pharmaceutical equivalents. We conclude
that generic and novel products perform equally well. In
other words, the generic products evaluated in this
study fulfill the requirements to be considered for use in
antimicrobial therapy.
We also designed an assay to determine critical con-
centrations using a few selected strains to confirm that
all the generic products evaluated were effective in anti-
microbial therapy. The results showed no significant dif-
ferences among samples (Tables 12 and 13). Moreover,
the ratios between the CC of the standard and those of
the different samples were similar to their potency levels
(Tables 14 and 15).
Along the same lines, an assay was designed to deter-
mine the production of spontaneous mutants in the diffu-
sion gel assay. The results again showed that all the
samples behaved similarly, leading us to conclude that
none of the samples studied differs markedly in their anti-
microbial activities. That is, generic and brand-name pro-
ducts that fulfill the international specifications for
manufacturing pharmaceutical products behave similarly
to novel products.
Our results are quite different from those of other stu-
dies [4-6]. Some of those studies were conducted using
the newest product as a “standard of comparison”,b u t
the researchers did not take into account that a com-
mercial product may have a range of content between
90% and 120%. Consequently, there will be great varia-
bility in the results with respect to the performance of
the antibiotic. For instance, if the novel drug product
has a hypothetical content of 120% relative to the
declared content on the label and the generic product
has a hypothetical content of 90%, then the effective
content of the generic product would be 75% (90/120)
of the novel drug. This could produce misleading results
because although both products fulfill the content
requirements, the first is at the upper limit and the sec-
ond at the lower limit. Other assays have compared
commercial antibiotic-discs with antibiotic-discs pre-
pared from solutions of commercial products. Again,
Table 14 Ratio of sample CC/standard CC for Meropenem
Sample Sample CC/standard CC ratio Ratio Median Content
P. a. 151 P. a. 157 E. c.6 9 E. c.5 0 A. b. 147 K. b.6 3
M1 106.8 106.9 106.8 106.8 106.8 106.5 106.8 107.5
M2 106.4 106.4 106.4 106.4 106.4 106.5 106.4 109.5
M3 107.3 107.3 107.2 107.3 107.3 107.5 112.5 105.3
M4 112.5 112.6 112.5 112.5 112.5 112.1 103.8 116.9
M5 103.8 103.9 103.7 103.9 103.8 103.7 104.6 104.5
M6 104.6 104.6 104.7 104.6 104.6 104.7 106.4 105.9
M7 106.4 106.4 106.4 106.4 106.4 106.5 113.4 107.2
M8 113.5 113.5 113.5 113.4 113.5 113.1 105.9 115.7
M9 105.9 105.9 105.9 105.9 105.9 105.6 104.1 107.2
M10 104.2 104.1 104.3 104.1 104.2 103.7 104.8 103.3
M11 104.8 104.8 104.9 104.8 104.8 104.7 105.9 105.7
M12 105.9 105.9 105.9 105.9 105.9 105.6 103.8 107.1
M13 103.8 103.9 103.7 103.9 103.8 103.7 102.6 102.5
M14 102.6 102.5 102.5 102.5 102.6 102.8 105.3 103.4
M15 105.3 105.3 105.3 105.2 105.3 105.6 103.7 106.2
M16 103.7 103.7 103.7 103.6 103.7 103.7 103.9 104.5
M17 103.9 103.9 103.9 103.9 103.9 103.7 105.0 105.1
M18 105.1 105.0 105.1 105.0 105.1 104.7 106.3 106.7
M19 106.2 106.2 106.3 106.2 106.2 106.5 105.6 105.8
M20 105.6 105.5 105.7 105.7 105.6 105.6 103.8 107.1
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Page 10 of 13Table 15 Ratio of sample CC/standard CC for Piperacillin/Tazobactam
Sample Sample CC/standard CC ratio Ratio Median Content
S. f. S. f. 29212 E. g. P. a.4 2 P. a.7 4 P. a. 151 S. a. 287
M1 103.9 103.8 104.6 104.0 104.7 104.8 104.2 104.3 103.6
M2 114.5 114.4 114.0 114.7 114.6 114.3 114.7 114.5 115.8
M3 108.9 108.6 108.1 108.0 108.5 108.7 109.0 108.5 109.7
M4 108.6 108.7 108.9 108.2 108.4 108.7 108.6 108.6 109.4
M5 108.3 108.0 108.3 108.4 108.0 108.3 108.4 108.3 108.7
M6 104.6 104.7 104.8 104.9 104.6 104.8 105.0 104.8 105.3
M7 109.0 109.8 109.6 109.9 109.8 109.5 109.8 109.6 110.5
M8 112.1 112.4 112.9 112.8 112.6 112.2 112.0 112.4 111.3
M9 105.2 105.1 104.9 105.5 105.8 105.4 104.8 105.3 104.2
M10 106.4 106.9 106.7 106.5 106.4 106.9 107.2 106.7 107.9
M11 115.6 115.4 115.8 115.2 115.8 116.0 115.9 115.7 116.8
M12 118.9 119.1 119.7 119.3 119.0 119.1 119.2 119.2 117.6
M13 113.1 113.0 113.7 113.1 113.0 113.8 113.6 113.3 114.3
M14 108.9 109.2 109.7 108.7 108.4 109.1 109.4 109.1 110.1
M15 110.5 110.9 110.7 110.8 110.5 110.8 110.4 110.7 110.1
M16 108.0 107.9 108.1 107.7 107.5 108.0 108.0 107.9 108.5
M17 111.9 111.1 111.7 111.8 111.2 111.7 111.9 111.6 112.6
M18 105.4 106.0 105.9 105.2 105.9 105.5 105.3 105.6 104.9
Table 16 Spontaneous mutant production in the diffusion gel assay for Meropenem
Sample A. b. 189 E. c.3 9 E. c.6 9 K. p.4 3 K. p.6 3
Median δ Median δ Median δ Median δ Median δ
Standard 25.333 1.366 205.333 5.354 43.333 2.582 43.333 2.582 203.167 2.137
M1 29.333 1.528 209.667 2.082 40.333 1.528 40.333 1.528 182.667 2.517
M2 22.667 1.528 207.333 1.528 46.333 3.055 46.333 3.055 198.667 4.041
M3 26.667 2.082 210.333 1.527 43.667 1.155 43.667 1.155 213.667 4.163
M4 22.000 2.000 208.000 2.000 44.667 1.528 44.667 1.528 200.000 6.245
M5 29.000 1.000 205.000 2.000 46.667 1.528 46.667 1.528 213.000 6.000
M6 29.333 2.082 209.667 1.155 41.333 1.528 41.333 1.528 196.667 7.095
M7 27.000 3.000 207.667 1.155 44.000 2.000 44.000 2.000 213.333 8.021
M8 23.000 2.000 207.667 1.155 45.667 1.528 45.667 1.528 202.333 6.110
M9 23.000 2.000 204.667 1.528 46.000 2.000 46.000 2.000 198.667 6.807
M10 29.000 2.000 202.333 2.517 47.667 1.528 47.667 1.528 213.667 8.083
M11 24.667 1.528 203.000 3.000 44.333 1.155 44.333 1.155 203.333 8.737
M12 26.667 1.528 210.000 1.000 40.000 1.000 40.000 1.000 188.333 4.163
M13 29.000 1.000 209.333 2.517 40.333 1.528 40.333 1.528 198.667 5.686
M14 24.667 1.155 202.667 3.786 44.333 1.528 44.333 1.528 203.667 6.110
M15 21.333 1.528 205.000 1.000 41.000 1.000 41.000 1.000 215.333 6.028
M16 28.333 1.155 208.667 1.528 44.667 1.528 44.667 1.528 199.000 4.000
M17 29.333 2.333 212.000 3.000 43.333 1.155 43.333 1.155 201.333 3.512
M18 23.667 1.155 205.000 1.000 46.000 1.000 46.000 1.000 209.000 9.165
M19 21.333 1.155 203.000 3.000 40.000 1.000 40.000 1.000 218.333 3.055
M20 23.333 2.516 204.667 2.082 45.667 1.155 45.667 1.155 210.333 7.095
F 8.715 3.571 6.076 4.683 7.294
Prob. 0.000 0.000 0.000 0.000 0.000
V C F 1.808 1.808 1.808 1.808 1.808
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Page 11 of 13the exact content of each antibiotic-disc and the exact
content of the product are unknown, so the results
could be misinterpreted.
It has been proposed that generic antibiotics behave
differently from the innovator product against patho-
genic microorganisms [4-6]. This is possible if the gen-
eric antibiotic does not fulfill the quality standards for
that pharmaceutical product (purity, content, etc.). For
instance, contaminants in generic drugs may interfere
with their antibiotic activities.
The MIC and MLC results obtained with different
pathogenic strains showed no differences among
samples (Tables 10 and 11). This is probably because
the samples were pharmaceutical equivalents. We con-
clude that generic and novel products perform equally
well. In other words, the generic products evaluated in
this study fulfill the requirements to be considered for
use in antimicrobial therapy.
Conclusions
All the samples analyzed by standardized microbiologi-
cal methods fulfill the requirements for content accord-
ing to USP XXVII. They all show the same
antimicrobial behavior because they have similar MIC,
MLC and CC values and produce similar numbers of
mutants.
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Table 17 Spontaneous mutant production in the
diffusion gel assay for Piperacillin/Tazobactam
Sample A. b. 189 P. a.5 4
Median δ Median δ
Standard 125.17 1.472 110.00 9.381
M1 127.00 1.000 109.33 1.528
M9 123.67 2.517 104.67 1.528
M18 124.33 1.528 105.00 1.000
M6 125.67 1.528 109.67 1.155
M10 127.67 3.055 102.33 2.517
M16 128.33 1.528 109.67 0.577
M5 128.00 1.000 105.00 2.000
M14 124.33 1.155 101.67 2.082
M4 122.67 0.577 108.00 2.000
M3 125.67 2.082 111.00 1.732
M15 123.33 2.082 105.00 1.000
M7 127.67 1.528 107.67 1.155
M8 123.00 1.732 107.67 1.155
M17 129.33 5.859 108.67 1.528
M13 126.67 1.155 107.00 2.000
M2 123.33 1.528 107.33 1.528
M11 125.33 1.528 103.00 3.000
M12 125.67 2.517 110.00 1.000
F 2.657 1.898
prob. 0.005 0.045
Figure 7 Determination of critical concentration of Piperacillin/
Tazobactam against E. gallinarum.
Figure 8 Diffusion gel assay testing the production of
spontaneous Meropenem-resistant mutants, with A. baumanii
147 as a control strain and K. pneumoniae 63 as a mutant-
producing strain.
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